IMO-8400

DRUG2 trials

Sponsors

Idera Pharmaceuticals, Inc.

Conditions

Diffuse Large B Cell LymphomaWaldenstrom's Macroglobulinemia

Phase 1

Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

TerminatedNCT02092909

Idera Pharmaceuticals, Inc.Waldenstrom's Macroglobulinemia

Start: 2014-03-31End: 2017-11-30Updated: 2019-09-10

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

CompletedNCT02252146

Idera Pharmaceuticals, Inc.Diffuse Large B Cell Lymphoma

Start: 2014-06-30End: 2016-12-31Updated: 2017-12-12

Related Papers

Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia

Blood2015-12-0311 citations